Global Osteoporosis Drugs Market Expected to Grow with a CAGR of 4.3% During the Forecast Period, 2019-2025 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Osteoporosis Drugs Market – By Drug Class (Bisphosphonates, Parathyroid Hormone Therapy, Selective Estrogen Receptor Modulator, RANK Ligand Inhibitors, Biosimilars, and Others), By Regions (North America, Europe, Asia Pacific, and Rest of the World) – Global Forecast up to 2025” report has been added to ResearchAndMarkets.com’s offering.

The author’s market research report predicts that the global osteoporosis drugs market will grow at a CAGR of 4.3% during the forecast period.

Overview of the Global Osteoporosis Drugs Market Research:

Osteoporosis or porous bone or thinning bones is a disease associated by low bone mass and bone tissue structural deterioration, resulting in bone fragility and enhanced risk of fractures of the spine, hip and wrist. It mainly effects elderly population, especially women who have already experienced menopause.

Upsurge in the prevalence of osteoporosis in postmenopausal women, increase in aging population, and increasing awareness among public about osteoporosis care are some of the important factors driving the market growth. Aging population is major risk factor for the development of osteoporosis, nearly 9.9 million people live with osteoporosis in US and an additional 43.1 million have low bone mineral density (BMD). However, expiration of the patents and side-effects associated with the drugs such as nausea, difficulty in swallowing, heartburn, and gastric ulcer are some of the factors that may prove detrimental for the market. Growing investment in R&D for drug discovery and development and rising healthcare expenditure is anticipated to enhance the revenue of osteoporosis drugs market in next five years.

International Osteoporosis Foundation estimates that around 200 million individuals globally suffer from osteoporosis disease. Currently, it is estimated that over 200 million people worldwide suffer from this disease. Nearly 30% of all postmenopausal women have osteoporosis in the US and in Europe. According to National Institute of Health, about 53 million individuals in US either suffer from osteoporosis or at an increased risk due to low bone mass. The increasing patient base for osteoporosis diseases ensures constant growth of the market during the forecast period 2019 to 2025.

According to the author analysis, North America accounted for the largest share of the global osteoporosis drugs market in 2018 and will retain a high position during the forecast period. North America is followed by Europe with a share of more than 20% of the global market in 2018.

Global Osteoporosis Drugs Market Research Competitive Analysis: The market is growing at a steady rate with a CAGR of 4.3% during the forecast period 2019-2025. There is an increase in new approvals, collaboration, and development of new osteoporosis drugs due to the increase in its incidence worldwide. For instance, FDA approved Evenity (romosozumab) to treat osteoporosis in postmenopausal women in April 2019 to those who have failed or intolerant to other osteoporosis therapies. South Korean based Yuyu Pharmaceutical launched Bazestar for the treatment of osteoporosis in late 2018. This drug is a selective estrogen receptor modulator used for treating and preventing osteoporosis in postmenopausal women.

In addition, other leading vendors are focusing on hugely investing in R&D activities to develop new drugs to obtain a high share in the market. Sandoz announced start of clinical study for its proposed biosimilar denosumab for osteoporosis in July 2019. Iran based AryoGen Pharmed is conducting phase III trial for biosimilar Prolia and the trial is expected to be completed by the end of this year.

Key Competitive Facts:

• Lasofoxifene (a new selective estrogen receptor modulator [SERM] or estrogen agonist-antagonist [EAA] with partial agonist activity at both estrogen receptors ER and ER); abaloparatide (a parathyroid hormone [PTH]-related protein analog); balicatib (inhibitors of the resorptive enzyme cathepsin K) are some of the molecules currently undergoing clinical trial for Food and Drug Administration approval.
• In March 2019, Pfenex announced an agreement with Alvogen to develop and commercialize PF708, a follow-on teriparatide product referencing Forteo to treat osteoporosis in the EU, some countries in North Africa, Middle East and other territories.

Key Topics Covered:

1 Industry Outlook

1.1 Industry Overview

1.1.1 Global Driver for Pharmaceutical Demand

1.1.2 R&D Pipeline in Pharmaceutical Industry

1.1.3 Top Pharma Drugs by Sales (In $Million)

1.2 Industry Trends

2 Report Outline

2.1 Report Scope

2.2 Report Summary

2.3 Research Methodology

2.4 Report Assumptions

3 Market Snapshot

3.1 Market Definition

3.2 Causes of Osteoporosis

3.3 Risk Factors for Osteoporosis

3.4 Symptoms of Osteoporosis

3.5 Segmented Addressable Market (SAM)

3.6 Trends of the Osteoporosis Drugs Market

3.7 Related Markets

3.7.1 Thrombosis Drugs

3.7.2 Immunotherapy Drugs

3.7.3 Oncology Drugs

4 Market Outlook

4.1 Market Segmentation

4.2 PEST Analysis

4.3 Porter 5 (Five) Forces

5 Market Characteristics

5.1 DRO -Market Dynamics

5.1.1 Drivers

5.1.2 Opportunities

5.1.3 Restraints

5.2 DRO – Impact Analysis

5.3 Key Stakeholders

6 Drug Class: Market Size and Analysis

6.1 Overview

6.2 Bisphosphonates

6.3 Parathyroid Hormone Therapy (PTH)

6.4 Selective Estrogen Receptor Modulator (SERM)

6.5 Rank Ligand Inhibitors

6.6 Biosimilars

6.7 Others

7 Regions: Market Size and Analysis

7.1 Overview

7.2 North America

7.3 Europe

7.4 APAC

7.4.1 Overview

7.5 Rest of the World

8 Competitive Landscape

8.1 Overview

9 Vendors Profile

9.1 Amgen, Inc.

9.2 Novartis AG

9.3 Eli Lilly & Company Ltd.

9.4 Pfizer Inc.

9.5 Radius Health, Inc.

10 Companies to Watch For

10.1 Teva Pharmaceutical Industries Ltd.

10.2 F. Hoffmann-La Roche Ltd.

10.3 GlaxoSmithKline plc

10.4 Novo Nordisk A/S

10.5 Merck & Co.

For more information about this report visit https://www.researchandmarkets.com/r/qy0g1v

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900